Inclusion Criteria:~* Male or female subjects aged 50 and above at the time of signing the Informed Consent
form~* Subjects who can understand and provide written informed consent (assent)~* Subjects who have diagnosis
of probable mild-to-moderate Alzheimer disease according to NINCDS-ADRDA (National Institute of Neurological
and Communicative Disorders and Stroke; Alzheimer's Disease and Related Disorders Association) criteria~*
Subjects who have MMSE Score of 16 to 26 at screening~* Subjects who are taking FDA-approved AD medications
(donepezil, galantamine, memantine, rivastigmine or their combinations) treatment on a stable dosage for at
least 3 months prior to screening.~* Subjects who have one (or more) identified adult caregiver who is able to
read, understand, and speak the designated language at the study site; either lives with the subject or sees
the subject for ≥2 hours/day ≥4 days/week; and agrees to accompany the subject to each study visit~* Subjects
who have a designated study partner who will accompany the subject to all clinic visits and participate in the
subject's clinical assessments~
